(Q38264376)

1 September 2017

1 reference

title

Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy (English)

1 reference

1 September 2017

1 reference

1

1 reference

1 September 2017

publication date

1 December 2014

1 reference

1 September 2017

published in

Current diabetes report

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

12

1 reference

1 September 2017

page(s)

563

1 reference

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

SGLT inhibitors in management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Insulin treatment and cardiovascular disease; friend or foe? A point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Carcinogenicity of some drugs and herbal products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-014-0563-4

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

21 January 2018

1 reference

12 December 2020

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results

1 reference

12 December 2020

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

1 reference

12 December 2020

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

1 reference

12 December 2020

Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes

1 reference

12 December 2020

10.1007/S11892-014-0563-4

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1015264362

0 references

1 reference